| Literature DB >> 35903003 |
Hany Ahmed1, Quentin Leyrolle2, Ville Koistinen1,3, Olli Kärkkäinen4, Sophie Layé5, Nathalie Delzenne2, Kati Hanhineva1,3,6.
Abstract
Alterations in the gut microbiota composition have been associated with a range of neurodevelopmental, neurodegenerative, and neuropsychiatric disorders. The gut microbes transform and metabolize dietary- and host-derived molecules generating a diverse group of metabolites with local and systemic effects. The bi-directional communication between brain and the microbes residing in the gut, the so-called gut-brain axis, consists of a network of immunological, neuronal, and endocrine signaling pathways. Although the full variety of mechanisms of the gut-brain crosstalk is yet to be established, the existing data demonstrates that a single metabolite or its derivatives are likely among the key inductors within the gut-brain axis communication. However, more research is needed to understand the molecular mechanisms underlying how gut microbiota associated metabolites alter brain functions, and to examine if different interventional approaches targeting the gut microbiota could be used in prevention and treatment of neurological disorders, as reviewed herein.Abbreviations:4-EPS 4-ethylphenylsulfate; 5-AVA(B) 5-aminovaleric acid (betaine); Aβ Amyloid beta protein; AhR Aryl hydrocarbon receptor; ASD Autism spectrum disorder; BBB Blood-brain barrier; BDNF Brain-derived neurotrophic factor; CNS Central nervous system; GABA ɣ-aminobutyric acid; GF Germ-free; MIA Maternal immune activation; SCFA Short-chain fatty acid; 3M-4-TMAB 3-methyl-4-(trimethylammonio)butanoate; 4-TMAP 4-(trimethylammonio)pentanoate; TMA(O) Trimethylamine(-N-oxide); TUDCA Tauroursodeoxycholic acid; ZO Zonula occludens proteins.Entities:
Keywords: Gut microbiota; gut-brain axis; metabolism; metabolites; short-chain fatty acids
Mesh:
Substances:
Year: 2022 PMID: 35903003 PMCID: PMC9341364 DOI: 10.1080/19490976.2022.2102878
Source DB: PubMed Journal: Gut Microbes ISSN: 1949-0976
Figure 1.Host metabolic homeostasis and neurological impact.
Gut microbiota-associated metabolites, their biological pathway, preclinical setups, and main outcomes and associations to clinical studies. Direction of outcomes are indicated by symbols as followed; increase (↑) and decrease (↓).
| Mechanism of action | Common name | Chemical formula | Origin | Preclinical model | Main preclinical outcomes | Clinical association | Reference |
|---|---|---|---|---|---|---|---|
| 3-(3-sulfooxylphenyl) propionic acid | C9H10O6S | Xenobiotic metabolism | SPF, GF and gnotobiotic C57BL/6 J mice | Fear extinction learning ↑ | n.a | [ | |
| 4-EPS | C8H10O4S | Tyrosine metabolism | C57BL/6 N MIA | Anxiety-like behavior ↑ | Fecal levels in ASD children ↑ | [ | |
| 5-AVAB | C5H11NO2 | Lysine metabolism | Fetal thalamocortical axonogenesis ↑ | n.a | [ | ||
| 5-AVA | C5H11NO2 | Lysine metabolism | Humanized and GF C57BL/6 miceBTBR T+ tf/J mice | Repetitive behavior ↓ | n.a | [ | |
| C7H8O | Tyrosine and phenylalanine metabolism | NOD mice | Social behavior ↓ | Fecal and urinary levels in ASD children ↑ | [ | ||
| Acetic acid | C2H4O2 | Dietary fiber fermentation | Obese C57BL/6 J mice dams and offspring | Social behavior ↑ | Altered fecal SCFA profiles in ASD children | [ | |
| Indole | C8H7N | Tryptophan metabolism | GF, SPF and | Neuronal maturation ↑ | n.a | [ | |
| 4-aminobenzoic acid | C7H7NO2 | Folate metabolism | SPF, GF and monocolonized C57Bl/6 J, Slc6a4 KO, Swiss Webster and Rag1 KO mice | EECs stimulation ↑ | n.a | [ | |
| C7H8O | Tyrosine and phenylalanine metabolism | Chronic (p.o.) or acute (iv, ip) administration to Wistar rats and C57BL/6 J or BTBR T+ tf/J mice | Altered brain dopamine metabolism | CSF levels ↑ in Alzheimer’s and Parkinson’s disease patients | [ | ||
| Butyric acid | C4H8O2 | Dietary fiber fermentation | EECs are stimulated by microbial metabolites | n.a | [ | ||
| Dopamine | C8H11NO2 | Tyrosine and phenylalanine metabolism | GF and SPF BALB/c mice | Gut microbes transform luminal dopamine and norepinephrine into biologically active form | n.a | [ | |
| GABA | C4H9NO2 | Glutamic acid metabolism | BALB/c mice treated with | Altered brain GABA and glutamate/glutamine levels | Altered GABA and glutamate in postmortem brains of persons with history of heavy alcohol use | [ | |
| Histamine | C5H9N3 | Phenylalanine and histidine metabolism | C57Bl/6 mice monocolonized with | Microbial histidine decarboxylase genes are enriched in patients with Chron’s disease | [ | ||
| Indole | C8H7N | Tryptophan metabolism | F344 rats monocolonized with | Acute GLP-1 secretion from EECs ↑ | n.a | [ | |
| Indole | C8H7N | Tryptophan metabolism | HEK-293 T mammalian cell cultures | Activation of EECs via TRP1 receptor ↑ | Indole derivatives were positively associated with memory scores | [ | |
| Kynurenic acid | C10H7NO3 | Tryptophan metabolism | Kynurenin aminotransferase II KO mice | Brain glutamate levels ↑ by limiting brain kynurenic acid supply | Decreased plasma tryptophan and kynurenic acid levels in patients with depressionCognitive functions negatively correlated to plasma kynurenine/tryptophan ratio | [ | |
| Lactate | C3H6O3 | Dietary fiber fermentation | Hooded rats treated with | Plasma and brain lactate ↑ | n.a | [ | |
| Pipecolic acid | C6H11NO2 | Lysine metabolism | GF and SPF BALB/c mice | Levels of pipecolic acid in the cerebrum ↑ in the presence of microbiota | n.a | [ | |
| Serotonin | C10H12N2O | Tryptophan metabolism | Circulating levels decrease in substance use disorders | [ | |||
| Tryptamine | C10H12N2 | Tryptophan metabolism | Humanized or | Activation of colonic serotonin receptor 4 ↑ | n.a | [ | |
| C13H16O7 | Tyrosine metabolism | Acute (i.p.) administration to C57BI/6 mice | BBB permeability ↓ | n.a | [ | ||
| Acetic acid | C2H4O2 | Dietary fiber fermentation | C57BL/6 J mice monocolonized with | BBB permeability ↓ | n.a | [ | |
| Butyric acid | C4H8O2 | Dietary fiber fermentation | C57BL/6 J mice monocolonized with | BBB permeability ↓ | n.a | [ | |
| Deoxycholic acid | C24H40O4 | Bile acid metabolism | Acute (i.v.) administration to sham or BDL-operated Sprague Dawley rats | Impairments in tight junction integrity | Serum levels associated with cognitive decline and cerebrospinal fluid t-tau aggregation in Alzheimer’s disease patients | [ | |
| Propionic acid | C3H6O2 | Dietary fiber fermentation | Human postmortem brain endothelium and CMEC/D3 cell cultures | Oxidative stress ↓ | n.a | [ | |
| TMA | C3H9N | Choline and carnitine metabolism | C57BL/6 J mice | Impairments in barrier integrity | n.a | [ | |
| TMAO | C3H9NO | Choline and carnitine metabolism | Chronic (i.p.) and acute (i.p.) administration to C57Bl/6 J mice | Improved barrier integrity | Cerebrospinal fluid levels ↑ in Alzheimer’s disease patients and associated with markers of Alzheimer’s disease | [ | |
| Ursodeoxycholic acid | C24H40O4 | Bile acid metabolism | Human BMEC cultures | Improved barrier integrity | Serum and postmortem brain levels ↑ in Alzheimer’s disease patients | [ | |
| Acetic acid | C2H4O2 | Dietary fiber fermentation | Chronic (p.o.) administration to GF and SPF C57BL/6 or 5× FAD micePrimary glia cell cultures | Microglial metabolism ↑ | n/a | [ | |
| Acetic acid | C2H4O2 | Dietary fiber fermentation | Chronic (p.o.) administration to GF C57BL/6 mice | Microglial activity ↑ | Brain amyloid load positively associated with plasma acetic acid and inversely associated with plasma butyric acid in patients with cognitive complaints | [ | |
| Dihydrocaffeic acid | C9H10O4 | Xenobiotic metabolism | Chronic (p.o.) administration to CD45.2+ C57BL/6 miceMice PBMC and neuron tissue cultures | Pro-inflammatory cytokine production ↓ | n.a | [ | |
| Indoxyl sulfate | C8H7NO4S | Tryptophan metabolism | Acute (i.p.) administration to C57BL/6 mice | Oxidative stress ↑ | CSF levels ↑ in patients with Parkinson’s diseaseUrinary levels positively associated to recurrent depressive symptoms | [ | |
| Indole | C8H7NO | Tryptophan metabolism | C57BL/6 J EAE and CX3CR1-AHR mice | Type 1-interferon signaling ↓ | Serum AhR activating tryptophan metabolites ↓ in patients with multiple sclerosis | [ | |
| C8H16N2O4 | Lysine metabolism | Chronic (i.p. or p.o.) administration to SPF and GF C57BL/6 mice | Oxidative stress in microglia ↑ | Associated with oxidative stress in brain tissue of elderly and patients with Alzheimer’s disease and/or diabetes mellitus | [ | ||
| Propionic acid | C3H6O2 | Dietary fiber fermentation | Acute (i.c.v or i.v.) administration to Western albino, Long-Evans, seizure-prone or seizure-resistant rats | Astrogliosis and microglial activity ↓ | n.a | 95–100 | |
| TMAO | C3H9NO | Choline and carnitine metabolism | Chronic (p.o.) administration to surgically or sham treated F344× BN F1 rats | Hippocampus oxidative stress ↑ | Positive and inverse associations with Parkinson’s or Alzheimer’s diseases | [ | |
| Urolithin A | C13H8O4 | Xenobiotic metabolism | Chronic (p.o.) administration to C57BL/6 EAE mice | Pro-inflammatory cytokine gene expression ↓ | n.a | [ | |
| 3M-4-TMAB | C8H18NO2C8H18NO2 | Carnitine metabolism | GF and SPF C57BL/6 J mice | Fatty acid oxidation in CNS white matter tissue ↓ | n.a | [ | |
| Acetic acid | C2H4O2 | Dietary fiber | Chronic (p.o. or i.p.) administration to | Improved cognitive functionsImproved mitochondrial function | n.a | [ | |
| Butyric acid | C4H8O2 | Dietary fiber fermentation | Chronic (i.c.v.) administration to Long-Evans rats | Locomotor activity ↑ | n.a | [ | |
| Butyric acid | C4H8O2 | Dietary fiber fermentation | Neuroblastoma or lymphoplastoid cell cultures derived from ASD males | Improved mitochondrial function | n.a | [ | |
| Ethanol | C2H5OH | Energy metabolism | SPF or humanized C57BL/6 J mice | Depression-like behavior ↑ | Microbial ethanol ↑ together with β-hydroxybutyrate ↓ in alcohol-dependent subject with behavioral alterations | [ | |
| Lactate | C3H6O3 | Energy metabolism | Chronic (p.o.) administration to CC042 miceC57BL/6NTac mice monocolonized with | Long-term memory formation ↑ | n.a | [ | |
| Indolepropionic acid | C11H11NO2 | Tryptophan metabolism | Mice neuro2a-APPsw cell cultures | Restoration of cell respiratory rate | n.a | [ | |
| 3-(3′-hydroxyphenyl) propionic acid | C9H10O3 | Xenobiotic metabolism | Chronic (p.o.) administration to Sprague-Dawley rats | Aβ plaque deposition ↑ | n.a | [ | |
| Ergothioneine | C9H15N3O2S | Histidine metabolism | Chronic (p.o.) administration to stressed Sprague Dawley rats or Aβ-injected C57BL/6 mice | Intracerebral oxidative stress ↓ | Plasma levels ↓ in patients with mild cognitive impairment or Parkinson’s disease | [ | |
| Ferulic acid | C10H10O4 | Xenobiotic metabolism | Rat pheochromocytoma cell culturesChronic (p.o.) administration corticosterone-treated Swiss mice, PSAPP mice or Sprague-Dawley rats with acute ischemia | Oxidative stress ↓ | n.a | [ | |
| Indolepropionic acid | C11H11NO2 | Tryptophan metabolism | SK-N-SH human neuroblastoma cell cultures | Neuronal apoptosis ↓ | n.a | [ | |
| Menadione | C11H8O2 | Energy metabolism | α-Synuclein fibril preparations | α-syn aggregation ↓ | n.a | [ | |
| TUDCA | C26H45NO6S | Bile acid metabolism | Chronic (p.o.) administration to APPPS1 mice | Aβ plaque deposition ↓ | n.a | [ | |
Abbreviations: 3 -M-4-TMAB, 3-methyl-4-(trimethylammonio)butanoate; 4-EPS, 4-ethylphenylsulfate;; 4-TMAP, 4-(trimethylammonio)pentanoate: 5-AVA(B), 5-aminovaleric acid (betaine); Aβ, amyloid beta protein; AD, Alzheimer’s disease; AhR, aryl hydrocarbon receptor; ASD, autism spectrum disorder; BDL, bile duct ligation; BMEC, brain microvascular endothelial cells; CCH, chronic cerebral hypoperfusion; CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis; EEC, enteroendocrine cell; GABA, γ-aminobutyric acid; GF, germ-free; I.C.V, intracerebroventricular; I.P., intraperitoneal; I.V., intravenous; MIA, maternal immune activation; NOD, nonobese diabetic; PBMC, peripheral blood mononuclear cell; P.O., per os; SCFA, short-chain fatty acid; SPF, specific-pathogen free; TBI, traumatic brain injury; TMA(O), trimethylamine(-N-oxide); TUDCA, tauroursodeoxycholic acid.
Figure 2.The integrity and selectivity of the blood–brain barrier in terms of microbial metabolites.
Figure 3.Communication routes between the gut and brain.
Figure 4.In the intersection of the gut–brain axis signaling: Selected microbiota metabolites and associated neurological functions.
Figure 5.Overlapping gut microbiota associated metabolites in neurological functions.
Gut microbial metabolites associated neurological functions, methods of preclinical models and presence in the human brain.
| Metabolite | Neurological function | Preclinical methods | Measured from human brain[ | Reference |
|---|---|---|---|---|
| 3-(3′-hydroxyphenyl)propionic acid | Neuroprotection | Yes | [ | |
| 3-(3-sulfooxyphenyl)propionic acid | Neurodevelopment | No | [ | |
| 3-hydroxybenzoic acid | Neuroprotection | Yes | [ | |
| 3M-4-TMAB | Neuronal energy metabolism | No | [ | |
| 4-aminobenzoic acid | Neurotransmission | No | [ | |
| 4-EPS | Neurodevelopment | No | [ | |
| 4-TMAP | Neuronal energy metabolism | No | [ | |
| 5-AVA | Neurodevelopment | Yes | [ | |
| 5-AVAB | Neurodevelopment | Yes | [ | |
| Acetic acid | Neurodevelopment | Yes | [ | |
| Butyric acid | Neurotransmission | Yes | [ | |
| Deoxycholic acid | Neurotransmission | Yes | [ | |
| Dihydrocaffeic acid | Neuroinflammation | No | [ | |
| Dopamine | Neurotransmission | Yes | [ | |
| Ethanol | Neuronal energy metabolism | Yes | [ | |
| Ergothioneine | Neuroprotection | Yes | [ | |
| Ferulic acid | Neuroprotection | No | [ | |
| GABA | Neurotransmission | Yes | [ | |
| Hippuric acid | Neurodevelopment | Yes | [ | |
| Histamine | Neurotransmission | Yes | [ | |
| Imidazole propionic acid | Neurodevelopment | No | [ | |
| Indole-3-aldehyde | Neurotransmission | No | [ | |
| Indole | Neurodevelopment, | Yes | [ | |
| Indolepropionic acid | Neuroinflammation | No | [ | |
| Indoxyl sulfate | Neurodevelopment | Yes | [ | |
| Isobutyric acid | Neurotransmission | Yes | [ | |
| Isovaleric acid | Neurotransmission | Yes | [ | |
| Kynurenic acid | Neurotransmission | Yes | [ | |
| Lactate | Neurotransmission | Yes | [ | |
| Neuroinflammation | Yes | [ | ||
| Norepinephrine | Neurotransmission | Yes | [ | |
| Neurodevelopment | Yes | [ | ||
| BBB integrity | No | [ | ||
| Phenethylamine | Neurotransmission | Yes | [ | |
| Phenylsulfate | Neurodevelopment | No | [ | |
| Pipecolic acid | Neurotransmission | Yes | [ | |
| Propionic acid | Neurodevelopment | Yes | [ | |
| Pyrocatechol sulfate | Neurodevelopment | No | [ | |
| Serotonin | Neurotransmission | Yes | [ | |
| Taurine | Neurodevelopment | Yes | [ | |
| TMA | BBB integrity | Yes | [ | |
| TMAO | Neurodevelopment | Yes | [ | |
| TUDCA | Neuronal energy metabolism | Yes | [ | |
| Tryptamine | Neurotransmission | Yes | [ | |
| Tyramine | Neurotransmission | Yes | [ | |
| Urolithin A | Neuroinflammation | No | [ | |
| Ursodeoxycholic acid | BBB integrity | Yes | [ | |
| Vitamins K | Neuroprotection | Yes | [ |
Abbreviations: 4-EPS, 4-ethylphenylsulfate; 5-AVA(B), 5-aminovaleric acid (betaine); BBB, blood–brain barrier; GABA, γ-aminobutyric acid; 3 M-4-TMAB, 3-methyl-4-(trimethylammonio)butanoate; 4-TMAP, 4-(trimethylammonio)pentanoate; TMA(O), trimethylamine(-N-oxide); TUDCA, tauroursodeoxycholic acid
| Some gut-derived metabolites such as trimethylamine- |